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Abstract: Antiviral prophylaxis with valganciclovir is used frequently in pediatric solid 
organ transplant patients to prevent Epstein–Barr virus (EBV)-induced infections and 
tissue-invasive disease including post-transplant lymphoproliferative disorder (PTLD). This 
approach is untested in clinical trials and valganciclovir dosing strategies in children are 
highly variable. Our objective was to characterize the pharmacokinetics of ganciclovir in 
the plasma of pediatric kidney and liver transplant patients taking valganciclovir for EBV 
prophylaxis. Virologic response was also evaluated. Ganciclovir was measured by liquid 
chromatography/ultraviolet detection. EBV DNA was quantified by TaqMan® polymerase 
chain reaction. NONMEM® VI was used for data analysis. Ganciclovir plasma profiles were 
consistent with a one-compartment model. Final model estimates of apparent oral clearance 
(L/h), apparent volume of distribution (L), and absorption rate constant were 7.33, 35.1, 
and 0.85, respectively. There was evidence of lower bioavailability in children younger than 
three years. All eight subjects achieved ganciclovir plasma concentrations above reported 
in vitro concentrations needed to inhibit EBV replication by 50%. However, four subjects 
had detectable EBV DNA with a median (range) of 18,300 (4,400 to 54,900) copies/mL of 
whole blood. These findings support the need for further studies of the clinical pharmacology 
and efficacy of valganciclovir for EBV prophylaxis.
Keywords: valganciclovir, ganciclovir, pharmacokinetics, Epstein–Barr virus, pediatrics, solid 
organ transplantation
Introduction
Antiviral prophylaxis with valganciclovir is used frequently in children after solid 
organ transplantation to prevent post-transplant lymphoproliferative disorder (PTLD), 
a tissue-invasive viral disease primarily induced by the Epstein–Barr virus (EBV).1–3 
Approximately 2000 pediatric solid organ transplants are performed annually in the 
United States.4 The incidence of PTLD in pediatric solid organ transplant patients 
ranges from 1% to 20% with mortality rates greater than 50% in some cohorts.5–7 Those 
children at the greatest risk for PTLD are EBV-antibody seronegative at the time of 
transplantation and receive an organ from an EBV-antibody seropositive donor.8–10
Valganciclovir, the oral prodrug of ganciclovir, with a 10-fold greater bioavailability, 
appears to reduce EBV viremia which can lead to the development of PTLD.11,12 Other 
data suggest that ganciclovir is protective against PTLD, particularly with prolonged 
use.10 Ganciclovir also has good in vitro activity against EBV. The ganciclovir 
concentration needed to inhibit viral replication by 50% (IC50) has been reported to 
be as low as 0.05 µM, which is attainable at valganciclovir doses used clinically.13 Clinical Pharmacology: Advances and Applications 2010:2 
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However, valganciclovir EBV prophylaxis has not been 
tested in randomized, placebo-controlled trials, and our 
knowledge about its efficacy is limited. In addition, the 
pharmacokinetics of this approach have not been established, 
and current pediatric valganciclovir dosing strategies are 
highly variable. The objective of this study was to characterize 
the pharmacokinetics of ganciclovir in pediatric kidney and 
liver transplant patients who were receiving valganciclovir 
for the prevention of EBV-associated PTLD.
Methods
subjects
This study was conducted at the University of Minnesota 
and the General Clinical Research Center. The University 
of Minnesota Institutional Review Board approved the 
study. Written informed consent was obtained from parents 
or guardians prior to participation. For children aged 7 to 
17 years, written informed assent was also obtained. Children 
younger than 18 years who were at least six weeks post-solid 
organ transplantation and receiving oral valganciclovir for 
anti-EBV prophylaxis were eligible for the study. Potential 
participants also had to have two stable serum creatinine 
measurements (defined as within ± 0.2 mg/dL of each other) 
obtained on two separate, consecutive occasions at least 
three days apart. Exclusion criteria were absolute neutro-
phil count less than 500 cells/mm3, platelet count less than 
20,000 cells/mm3, and hemoglobin less than 6.5 g/dL.
study design
This was a prospective, open-label pharmacokinetic study. 
Potential participants were initially identified by their primary 
providers at the University of Minnesota Transplant Center 
and referred to the research team for the study. The study 
consisted of a 12-hour study visit at the General Clinical 
Research Center and/or two study visits scheduled as part 
of routine transplant clinic appointments. Subjects could 
participate in one or both study visit categories, and their 
selection was documented in the consent and assent forms.
For the 12-hour study visit, subjects arrived at the General 
Clinical Research Center after an overnight fast, and had a 
saline lock placed in one arm to obtain serial venous blood 
samples for plasma ganciclovir concentrations. The date, 
time, and amount of the subject’s last valganciclovir dose 
were recorded. Blood was drawn for a complete blood cell 
count with differential, electrolytes, serum creatinine, and 
a baseline ganciclovir plasma concentration. Subjects were 
given a standardized breakfast (641 Kcal; 5.1% protein, 12.7% 
carbohydrates, 3.4% fat) and immediately after completing 
the meal took a dose of their own supply of valganciclovir 
with up to 237 mL of water. Additional blood samples were 
drawn at 1, 2, 4, 6, 8, and 12 hours post-dose.
For the two study visits that occurred as part of regularly 
scheduled transplant clinic appointments, subjects had 
blood drawn for ganciclovir plasma concentrations at the 
start and at the end of the appointments. The date, time, and 
amount of the last valganciclovir dose were recorded along 
with the sample draw time.
Throughout the study, subjects also had blood drawn at 
their regular transplant clinic appointments for routine quan-
titative EBV DNA (qEBV) analysis. The qEBV assays were 
performed at the University of Minnesota Medical Center’s 
Clinical Virology Laboratory using a validated method.14,15 
Quantitative EBV DNA data were reported as viral copies per 
mL of whole blood. The reliable limit of detection of the assay 
was 10 copies/reaction (coefficient of   variation (CV%), 30%), 
which equates to 1000 copies/mL of whole blood. These 
clinical data were used to evaluate EBV replication among 
study participants.
Quantitation of ganciclovir in plasma
Plasma concentrations of ganciclovir were measured using a 
validated reversed phase high-performance liquid chromatog-
raphy assay. Plasma (200 µL) was subjected to protein precipi-
tation with perchloric acid. The injection volume was 25 µL of 
pH adjusted, protein free extract. The mobile phase consisted of 
97.5% phosphate buffer (25 mM at pH 6) and 2.5% acetonitrile 
(vol/vol). The stationary phase was a 3 mm × 150 mm YMC 
C4 reversed phase column (Waters Corporation, Milford, MA). 
The flow rate was 0.4 mL/min with detection at 266 nm. All 
analytic measurements were performed using an HP series 
1100 LC system (Agilent Technologies, Palo Alto, CA). The 
assay internal standard was dideoxycytidine. Plasma standards 
ranged from 25 to 10,000 ng/mL. Accuracy and variability 
were determined using four quality controls (25, 75, 750, and 
7,500 ng/mL) measured in triplicate on five separate days. 
A single factor analysis of variance was used for statistical 
analysis. Accuracy ranged from 97.4% to 106.6%. Within- and 
between-assay variability, expressed as CV%, ranged from 
0.4% to 3.3% and 0.8% to 5.3%, respectively.
Pharmacokinetic analysis
Ganciclovir plasma concentration-time data from the 12-hour 
study visit and the two study visits that occurred during 
regularly scheduled transplant clinic appointments were 
combined and analyzed using a nonlinear mixed-effects 
modeling approach to determine ganciclovir pharmacokinetic Clinical Pharmacology: Advances and Applications 2010:2 
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parameters. Doses for valganciclovir were recorded as 
milligrams of valganciclovir and not corrected for molecular 
weight differences between ganciclovir and valganciclovir. 
The model estimated parameters, apparent oral clearance 
(CL/F), and apparent volume of distribution (V/F) 
implicitly incorporate this difference into the bioavailability 
(F) term.
NONMEM® version VI, level 2.0 with PDxPOP ver-
sion 3.0 (LLC, Globomax, Ellicott City, MD) and Compaq 
(Digital) Visual Fortran 6.0 Compiler (Houston, TX) were 
used for data analysis.16 Oral doses of valganciclovir were 
administered into an absorption depot compartment. Absorp-
tion of valganciclovir was modeled as a first-order process 
and conversion to ganciclovir in the central compartment was 
assumed to be instantaneous. A one-compartment model with 
first order elimination for ganciclovir disposition in plasma 
was specified with ADVAN2 and TRANS2. The model was 
parameterized in terms of CL/F, V/F, and absorption rate 
constant (Ka).
Between-subject variabilities on CL/F, V/F, and Ka were 
modeled using a proportional error model. This imposed 
a log normal distribution on the parameters with results 
expressed as a CV%. Residual unexplained variability was 
assumed to have a log normal distribution and was also 
expressed as a CV%. The estimation method implemented 
for all runs was the first-order conditional estimation with 
interaction method. Four significant figures were specified 
for the estimation procedure.
During the model development process, the importance 
of a patient-specific covariate on the pharmacokinetic 
parameters was determined using a generalized additive 
model analysis and the likelihood ratio test. The likeli-
hood ratio test, which is approximately χ2 distributed, is 
the primary statistic used to compare two nested models, 
and the objective function value is a measure of goodness 
of fit. When a covariate is added to the model, a statisti-
cally significant (α = 0.05) improvement in the model 
is associated with an objective function value drop of 
3.84 units. The covariates available for model building were 
age, weight, height, body surface area, creatinine clearance 
by the Schwartz method, transplant type (kidney or liver), 
and sex.17–19
Metrics of ganciclovir exposure
Because a range of doses was administered to the subjects, 
the ganciclovir exposure metric of interest was the area under 
the concentration-time curve from time 0 to infinity (AUCinf). 
This metric was derived from the empirical Bayes estimates 
of an individual’s clearance parameter and the valganciclovir 
dose that subject received.
Additional statistical analyses
As this was an exploratory analysis, no formal sample size 
calculations were performed to power a particular statistical 
test. All demographic, pharmacokinetic, and clinical data 
are summarized descriptively.
Results
study population
Thirty-two patients were screened for the study. Eight patients 
receiving valganciclovir for EBV prophylaxis were enrolled 
in the study (Table 1) and included in the pharmacokinetic 
analysis. Of these eight subjects, two participated in both 
the intensive and sparse sampling study visit categories. The 
remaining six subjects participated in the sparse sampling 
study visit that took place during two of their regularly 
scheduled transplant clinic appointments. All eight subjects 
were taking a valganciclovir suspension that contained 
90 mg/mL and was prepared by the University of Minnesota 
Medical Center’s Fairview Specialty Pharmacy. The median 
(range) doses administered were 11.1 (10.1 to 12.1) mg/kg 
every 12 hours and 7.4 (5.3 to 11.3) mg/kg every 24 hours.
ganciclovir pharmacokinetics
A total of 43 plasma samples were available for determination 
of ganciclovir concentrations and used in the pharmacokinetic 
analysis. The observed ganciclovir plasma concentration-
time data are presented in Figure 1. An attempt was made to 
Table  Baseline subject characteristics (n = 8)
Characteristic Median value Range 
Age, years 2.1 1.3–6.2
Weight, kg 14.1 9.4–19.8
height, cm 89.5 73–107
Body surface area,1 m2 0.6 0.4–0.7
Creatinine clearance,2 ml/min/1.73 m2 106 61.9–127
sex, n (%)
  a.  Male 6 75
  b.  Female 2 25
Organ transplant, n (%)
  a.  Kidney 5 63
  b.  Liver 3 37
Notes: 1Body surface area (m2) = the square root of [(weight (kg) × height (cm))/3600]; 
2schwartz method: [k × height (cm)]/[serum creatinine (mg/dL)] where k = 0.45 for 
patients aged 2 years, and k = 0.55 for boys aged 2 to 13 years and girls aged 2 
to 16 years.17–19Clinical Pharmacology: Advances and Applications 2010:2 
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fit these data to a two-compartment pharmacokinetic model 
in addition to a one-compartment model. The regression 
for the two-compartment model did not converge and the 
one-compartment model was chosen as the final pharma-
cokinetic model.
All parameter estimates and their relative standard 
errors for the final model are shown in Table 2. A plot of 
the observed versus the concentrations predicted under 
the regression model is presented in Figure 2. Standard 
diagnostic plots suggested that the model was adequate to 
describe the data (data not shown). During model develop-
ment an inverse relationship was observed for CL/F versus 
weight and CL/F versus age (Figures 3a and b). This is con-
trary to what was expected as CL (expressed in L/h) usually 
increases with an increase in body size (eg, weight, age, 
body surface area). However, in this case, the pharmacoki-
netic parameter is CL/F. We hypothesized that as age and 
weight increased, bioavailability could also be changing and 
confound the apparent relationship with CL. We explored an 
age effect on bioavailability to test this hypothesis and found 
evidence of decreasing bioavailability (F less than 65%) in 
subjects younger than three years compared with subjects 
older than three years but the signal was not sufficiently 
strong in this limited sample size to demonstrate statistical 
significance. Overall, none of the patient-specific covari-
ates tested contributed statistically significant information 
about ganciclovir pharmacokinetic parameters. The median 
(range) post hoc estimated individual ganciclovir AUCinf was 
26.9 (16.5 to 51.5) ng . L/h for subjects with valganciclovir 
dosing every 12 hours and 13.5 (4.84 to 22.1) ng . L/h for 
dosing every 24 hours.
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Figure  Concentration-time profile for ganciclovir in plasma following oral valganciclovir dosing.
Table  ganciclovir plasma pharmacokinetic parameters in 
8 subjects following oral valganciclovir dosing
Parameter Estimate Relative SE
CL/F (L/h) 7.33 10.2%
V/F (L) 35.1 1.19%
Ka 0.85 20.8%
Variability in CL/F (CV%) 36.3% 25.5%
Variability in V/F (CV%) 41.4% 48.7%
Variability in Ka (CV%) 74.3% 237%
RUV (CV%) 33.5% 50.0%
Abbreviations: CL/F, apparent oral clearance; V/F, apparent volume of distribution; 
Ka, absorption rate constant; RUV, residual unexplained variability; CV, coefficient of 
variation for the between subject variability in the population; relative se, measure 
of precision computed by dividing the standard error (se) by the value of the 
estimate × 100.Clinical Pharmacology: Advances and Applications 2010:2 
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Quantitative eBV DnA evaluations
Six out of eight subjects were EBV-antibody seronegative 
prior to transplantation. Five of these subjects seroconverted 
after receipt of their transplanted organ. During the study 
period, four out of eight subjects had undetectable qEBV 
measurements. In the remaining four subjects, the median 
(range) qEBV was 18,300 (4,400 to 54,900) copies/mL of 
whole blood. During the study, the median (range) duration 
of EBV viremia was 113.5 (36 to 238) days. In all eight 
subjects, measured ganciclovir plasma concentrations were 
well above the reported in vitro IC50 for EBV (as low as 
0.05 µM or 12.8 ng/mL).13 No subject in our cohort developed 
EBV-associated PTLD.
Discussion
Ours is the first report of the pharmacokinetics of ganciclovir 
following valganciclovir administration for the prevention 
of EBV-associated PTLD in pediatric kidney and liver 
transplant patients. Pharmacokinetics and drug exposure 
data are emerging for valganciclovir when it is used for the 
treatment of congenital cytomegalovirus (CMV) infection in 
neonates and for the prevention of CMV disease in children 
receiving solid organ transplantations.12,20–25 Our median 
(range) ganciclovir AUCinf of 26.9 (16.5 to 51.5) ng . L/h 
and 13.5 (4.84 to 22.1) ng . L/h for every 12-hour and every 
24-hour dosing period, respectively, compare reasonably 
well to mean ± standard deviation (SD) daily AUC values 
of 51.8 ± 11.9 µg . h/mL, 61.7 ± 29.5 µg . h/mL, and 
58.0 ± 21.8 µg . h/mL reported for pediatric kidney, liver, and 
heart transplant patients, respectively, who were receiving 
valganciclovir CMV prophylaxis. The study by Vaudry and 
colleagues25 did not report parameter estimates for CL/F, V/F, 
and Ka. In addition, the investigators assessed ganciclovir 
pharmacokinetics after using a novel valganciclovir dosing 
algorithm that incorporated creatinine clearance by the 
Schwartz method and body surface area. Our transplant 
center uses weight-based valganciclovir dosing adjusted for 
changes in renal function. Different dosing strategies between 
institutions could explain the lower AUC estimates observed 
in some of our subjects who were receiving valganciclovir 
every 24 hours.
We also observed an inverse relationship between 
CL/F and age and CL/F and weight during covariate model 
development. Furthermore, we found evidence of a lower F 
in children younger than three years compared with children 
older than three years although this was not statistically signif-
icant. We attributed our findings to physiologic changes in bio-
availability that occur during human growth and development. 
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Figure  Observed versus model-predicted ganciclovir concentrations in plasma following oral valganciclovir dosing in eight subjects.
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The oligopeptide transporter PEPT1 facilitates the absorption 
of valganciclovir from the small intestine.26 Even though little 
is known about the ontogeny of PEPT1 in humans, its expres-
sion has been shown to change markedly during early devel-
opment in animal models.27 Larger pharmacokinetic studies 
are needed to thoroughly explore inter-subject variability in 
F and the potential impact of bioavailability differences on 
valganciclovir dosing in children.
All eight subjects in our study achieved ganciclovir 
concentrations well above the reported in vitro IC50 value 
for EBV but caution must be exercised when comparing 
in vitro concentrations to those measured in vivo because of 
known differences in protein binding. However, only half of 
the subjects had undetectable qEBV measurements while 
receiving valganciclovir prophylaxis. This may have been 
due to multiple factors including inconsistent medication 
adherence, the presence of a resistant strain of EBV , or the 
circulation of latent, nonreplicating EBV DNA, which is not 
susceptible to antiviral therapy.
Conclusions
In conclusion, ganciclovir pharmacokinetics in pediatric 
kidney and liver transplant patients receiving valganciclovir 
for the prevention of EBV-associated PTLD were well 
described by a one-compartment model. Bioavailability 
varied across subjects and based on moderately strong 
negative correlations between CL/F and age and CL/F and 
weight, F appears to be lower in children younger than 
three years. Virologic response to valganciclovir EBV 
prophylaxis was also variable. These data suggest that a larger 
clinical study of this preventative approach in pediatric solid 
organ transplant patients is warranted.
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